fianlimab

Regeneron Provides Update on Phase 3 Trial of Fianlimab (LAG-3 Inhibitor) Combination in First-Line Unresectable or Metastatic Melanoma

May 15, 2026 20:19 ET  | Source: Regeneron Pharmaceuticals, Inc. The trial did not reach statistical significance for the primary…

2 hours ago